Effects of the Janus kinase inhibitor, tofacitinib, on testicular Leydig cell hyperplasia and adenoma in rats, and on prolactin signaling in cultured primary rat Leydig cells

Toxicological Sciences

Volumn 155, Issue 1, 2017, Pages 148-156

  Chapin, Robert E ^a   Ball, Douglas J ^a   Radi, Zaher A ^a   Kumpf, Steven W ^a   Koza Taylor, Petra H ^a   Potter, David M ^a   Mark Vogel, W ^a  

^a PFIZER INC   (United States)

Author keywords

In vitro; JAK1 3 inhibitor; Leydig cell tumor; LH receptor; Primary rat Leydig cell; STAT5

Indexed keywords

JANUS KINASE 2; LUTEINIZING HORMONE RECEPTOR; MESSENGER RNA; PROLACTIN; STAT5 PROTEIN; TOFACITINIB; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADENOMA; ADULT; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL HYPERPLASIA; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FIBROADENOMA; HISTOPATHOLOGY; IN VITRO STUDY; LEYDIG CELL; LEYDIG CELL TUMOR; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SURVIVAL RATE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERPLASIA; METABOLISM; PATHOLOGY; TESTIS;

ADENOMA; ANIMALS; HYPERPLASIA; LEYDIG CELLS; MALE; PIPERIDINES; PROLACTIN; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RATS; SIGNAL TRANSDUCTION; TESTIS;

EID: 85014390487     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfw197     Document Type: Article

References (45)

1. Ault, B. (1996). Review and evaluation of pharmacology/toxicology data (ropinirole hydrochloride). NDA 20-658. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020658_requip_toc.cfm. Accessed May 22, 2015
2. Aragona, C., Bohnet, H. G., and Friesen, H. G. (1977). Localization of prolactin binding in prostate and testis: The role of serum prolactin concentration on the testicular LH receptor. Acta Endocrinol. 84, 402-409.
3. Biegel, L. B., Cook, J. C., and Hurtt, M. E. (1993). Isolation and primary culture of Leydig cells. In Methods in Toxicology, vol 3A, Male Reproductive Toxicology (R. E. Chapin and J. J. Heindel, Eds.), 1st edn., pp. 182-196. Academic Press, San Diego, CA.
4. Catt, K. J., and Dufau, M. L. (1973). Spare gonadotropin receptors in rat testis. Nature 244, 219-221.
5. Chapin, R. E., and Creasy, D. M. (2012). Assessment of circulating hormones in regulatory studies II. Male reproductive hormones. Toxicol. Pathol. 40, 1063-1078.
6. Chilton, B. S., and Hewetson, A. (2005). Prolactin and growth hormone signaling. Curr. Topics Dev. Biol. 68, 1-23.
7. Cho, W. S., Han, B. S., Nam, K. T., Park, K., Choi, M., Kim, S. H., Jeong, J., and Jang, D. D. (2008). Carcinogenicity study of 3-monochloropropane-1, 2-diol in Sprague-Dawley rats. Food Chem. Toxicol. 46, 3172-3177.
8. Christensen, A. K., and Peacock, K. C. (1980). Increase in Leydig cell number in testes of adult rats treated chronically with an excess of human chorionic gonadotropin. Biol. Reprod. 22, 383-391.
9. Clegg, E. D., Cook, J. C., Chapin, R. E., Foster, P. M. D., and Daston, G. P. (1997). Leydig cell hyperplasia and adenoma formation: Mechanisms and relevance to humans. Reprod. Toxicol. 11, 107-121.
10. Cook, J. C., Hurtt, M. E., Frame, S. R., and Biegel, L. B. (1994). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in Crl:CD_BR (CD) rats. Toxicologist (Abstr.) 14, 301.
11. Cook, J. C., Klinefelter, G. R., Hardisty, J. F., Sharpe, R. M., and Foster, P. M. D. (1999). Rodent Leydig cell tumorigenesis: A review of the physiology, pathology, mechanisms and relevance to humans. Crit. Rev. Toxicol. 29, 169-261.
12. Ellis, G. B., and Desjardins, C. (1982). Male rats secrete luteinizing hormone and testosterone episodically. Endocrinology 110, 1618-1627.
13. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). (2013). European Public Assessment report for Xeljanz (tofacitinib). EMA/CHMP/425279/2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002542/WC500154697.pdf. Accessed August 30, 2016.
14. Gilliland, F. D., and Key, C. R. (1995). Male genital cancers. Cancer 75 (Suppl 1), 295-315.
15. Grizard, G., Andre, M., Jarrige, J. F., Chambon, M., and Boucher, D. (1983). Effects of bromocriptine on pituitary-testicular function in the rat: Possible inhibition of in vitro production of androgen by Leydig cells. Int. J. Androl. 6, 563-574.
16. Harleman, J. H., Hargreaves, A., Andersson, H., and Kirk, S. (2012). A review of the incidence and coincidence of uterine and mammary tumors in Wistar and Sprague Dawley rats based on the RITA database and the role of prolactin. Toxicol. Pathol. 40, 926-930.
17. Heller, C. G., and Leach, D. R. (1971). Quantification of Leydig cells and measurement of Leydig cell size following administration of human chorionic gonadotropin to normal men. J. Reprod. Fertil. 25, 185-192.
18. Hubert, M. F., Laroque, P., Gillet, J. P., and Keenan, K. P. (2000). The effects of diet, ad libitum feeding, and moderate and severe dietary restriction on body weight, survival, clinical pathology parameters, and cause of death in control Sprague-Dawley rats. Toxicol. Sci., 195-207.
19. Huhtaniemi, I., Bolton, N., Leinonen, P., Kontturi, M., and Vihko, R. (1982). Testicular luteinizing hormone receptor content and in vitro stimulation of cAMP and steroid production: A comparison between man and rat. J. Clin. Endocrinol. Metab. 55, 882-889.
20. Jabbour, H. N., and Lincoln, G. A. (1999). Prolactin receptor expression in the testis of the ram: Localisation, functional activation and the influence of gonadotrophins. Mol. Cell. Endocrinol. 148, 151-161.
21. Jin, K. (1996). Statistical review and evaluation. NDA 20-658 (ropinirole hydrochloride). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020658_requip_toc.cfm. Accessed May 22, 2015.
22. Kanzaki, M., and Morris, P. L. (1998). Lactogenic hormoneinducible phosphorylation and gamma-activated sitebinding activities of STAT5B in primary rat Leydig cells and MA-10 mouse Leydig tumor cells. Endocrinology 139, 1872-1882.
23. Liu, X., Robinson, G. W., Gouilleux, F., Groner, B., and Henninghausen, L. (1995). Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Nat. Acad. Sci. USA 92, 8831-8835.
24. Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408.
25. Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., et al. (2010). Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis. J. Inflamm. (Lond) 7, 41.
26. Prentice, D. E., and Meikle, A. W. (1995). A review of druginduced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Hum. Exp. Toxicol. 14, 562-572.
27. Prentice, D. E., Siegel, R. A., Donatsch, P., Qureshi, S., and Ettlin, R. A. (1992). Mesulergine-induced Leydig cell tumors, a syndrome involving the pituitary-testicular axis on the rat. In Medical Toxicology, (H. M. Bolt, F. A. de Wolff, and P. T. Henderson, Eds.), pp 197-204. Springer-Verlag, Berlin.
28. Rawlings, J. S., Rosler, K. M., and Harrison, D. A. (2004). The JAK/STAT signaling pathway. J. Cell Sci. 117, 1281-1283.
29. Roberts, S. A., Nett, T. M., Hartman, H. A., Adams, T. E., and Stoll, R. E. (1989). SDZ 200-110 induces Leydig cell tumors by increasing gonadotropins in rats. J. Am. Coll. Toxicol. 8, 487-505.
30. Roberts, S. A., Robison, R. L., Van Ryzin, R. J., and Stoll, R. E. (1993). Increased incidence of Leydig cell tumors in male rats with the dopaminergic agonist SDZ 205-502. Toxicologist (Abstr) 13, 194.
31. Roney, P. L. (2006). Review of pharmacology/toxicology data. NDA 21-829 (rotigotine hydrochloride). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021829s000TOC.cfm. Accessed May 22, 2015.
32. Salva, A., Klinefelter, G. R., and Hardy, M. P. (2001). Purification of rat Leydig cells: Increased yields after unit-gravity sedimentation of collagenase-dispersed interstitial cells. J. Androl. 22, 665-671.
33. Sodersten, P., Eneroth, P., and Pettersson, A. (1983). Episodic secretion of luteinizing hormone and androgen in male rats. J. Endocrinol. 97, 145-153.
34. Schmittgen, T. D., and Livak, K. J. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101-1108.
35. Steele, T. D. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Review and evaluation of pharmacology and toxicology data (part 6). NDA 20-667, pramipexole dihydrochloride. Undated (NDA approval date 01 July 1997). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020667.cfm. Accessed March 6, 2015.
36. Tukey, J. W., Ciminera, J. L., and Heyse, J. F. (1985). Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41, 295-301.
37. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2012). Pharmacology Review(s), New Drug Application 203214, Xeljanz (tofacitinib citrate). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000TOC.cfm. Accessed August 30, 2016.
38. Wahlstrom, T., Huhtaniemi, I., Hovatta, O., and Seppala, M. (1983). Localization of luteinizing hormone, folliclestimulating hormone, prolactin and their receptors in human and rat testis using immunohistochemistry and radioreceptor assay. J. Clin. Endocrinol. Metab. 57, 825-830.
39. Waeber, C., Reymond, O., Reymond, M., and LeMarchand-Beraud, T. (1983). Effects of hyper-and hypoprolactinemia on gonadotropin secretion, rat testicular luteinizing hormone/human chorionic gonadotropin receptors and testosterone production by isolated Leydig cells. Biol. Reprod. 28, 167-177.
40. Walsh, P. C. (1977). The endocrinology of testicular tumors. Recent results. Cancer Res. 60, 196-201.
41. Watson, C. J., and Burdon, T. G. (1996). Prolactin signal transduction mechanisms in the mammary gland: The role of the Jak/Stat pathway. Rev. Reprod. 1, 1-5.
42. Welsch, C. W., and Aylsworth, C. F. (1983). Relation of the neuroendocrine system to the development of mammary tumors in rats during aging. In Neuroendocrinology of Aging (J. Meites, Ed.), pp. 333-352. Plenum Press, NY, NY.
43. Yamada, T., Nakamura, J., Murakami, M., Okuno, Y., Hosokawa, S., Matsuo, M., Yamada, H. (1994). The correlation of serumluteinizing hormone levels with the induction of Leydig cell tumors in rats by oxolinic acid. Toxicol. Appl. Pharmacol. 129, 146-154.
44. Xeljanz, tofacitinib tablets, Canadian Product Monograph. Pfizer Canada Inc. (2014). Avialable at: http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00024828. Accessed March 6, 2015.
45. Zipf, W. B., Payne, A. H., Kelch, R. P. (1978). Prolactin, growth hormone, and luteinizing hormone in the maintenance of testicular luteinizing hormone receptors. Endocrinology 103, 595-600.